1558003-75-0Relevant academic research and scientific papers
CHEMICAL COMPOUNDS
-
Paragraph 0374-0376, (2020/12/01)
The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
A straightforward and efficient synthesis of praziquantel enantiomers and their 4′-hydroxy derivatives
Cedillo-Cruz, Alberto,Aguilar, Maria Isabel,Flores-Alamo, Marcos,Palomares-Alonso, Francisca,Jung-Cook, Helgi
, p. 133 - 140 (2014/02/14)
A new method for the synthesis of praziquantel enantiomers via resolution of praziquanamine with (S)-(+)-naproxen was developed. The four 4′-hydroxy derivatives were obtained through each single praziquanamine enantiomer, coupling with cis- and trans-4-(benzyloxy)cyclohexanecarboxylic acids and subsequent hydrogenolysis for the deprotection of the 4′-OH cyclohexane residue. Additionally, the in vitro cysticidal activity of the compounds was tested, finding that (R)-(-)-praziquantel is the eutomer.
